lucky wallpaper

lucky wallpaper IBIDEN, the dominant supplier of chip package substrates used in Nvidia’s cutting-edge semiconductors, may need to dial up the pace of production capacity increases to keep up with demand, according to its chief executive officer. Sales of the 112-year-old company’s artificial intelligence (AI) use substrates are robust with customers buying up all that Ibiden has, CEO Koji Kawashima said, adding that that demand is likely to last at least till next year. Ibiden is building a new substrate factory in Gifu prefecture, central Japan, expected to go online at 25 per cent production capacity around the last quarter of 2025 before reaching 50 per cent by March 2026. But that may not be enough, Kawashima said. The company is in talks about when to get the remaining 50 per cent of capacity online. “Our customers have concerns,” he said. “We are already being asked about our next investment and the next capacity expansion.” Ibiden’s clients include Intel, Advanced Micro Devices, Samsung Electronics and Taiwan Semiconductor Manufacturing Company, as well as Nvidia, according to data compiled by Bloomberg. Many of them consult with the Japanese company early in product development, because the substrates – which help transmit signals from semiconductors to the circuit board – need to be tailored for each chip. Substrates must be made to withstand the heat of an Nvidia graphics processing unit to form an AI chip package complete with components such as memory. Founded as a power utility company in 1912, Ibiden developed semiconductor expertise through a partnership with Intel that Kawashima cultivated by waiting every day in front of the Santa Clara company to stop engineers and executives for product feedback in the early 1990s. At one point, Intel comprised around 70 per cent to 80 per cent of Ibiden’s revenue from chip package substrates. That fell to around 30 per cent in the fiscal year ended March as the US chipmaker struggled to execute a turnaround that recently saw the ousting of CEO Pat Gelsinger. Reliance on Intel has hurt Ibiden’s stock, down around 40 per cent this year. In October, Ibiden revised down its profit outlook after sluggish demand for components used in general purpose servers outweighed AI server-related growth. But while noting it was important to expand business with chipmakers other than Intel, Kawashima said he was confident Intel will bounce back. “Intel’s overall technology is very sophisticated,” the 61-year-old said. “Intel raised us up and opened so many doors. Our relationship with Intel will always be our treasure, and Intel will forever be an important customer.” With many foreign chipmakers unwilling to transfer their latest technology to the US, Intel is likely to play a key role in Washington’s goal to boost cutting-edge semiconductor production capabilities at home, Kawashima said. Ibiden itself has no manufacturing facilities in the US. It has no plans to build any due to the cost of labour and logistics, Kawashima said, irrespective of US president-elect Donald Trump’s plans to impose tariffs on a wide range of products. All of Nvidia’s AI semiconductors now use Ibiden’s substrates, although Taiwanese rivals such as Unimicron Technology are eyeing the field. But it will not be easy to break Ibiden’s position as a dominant supplier, according to Toyo Securities analyst Hideki Yasuda. “Nvidia’s AI chips need sophisticated substrates, and Ibiden is the only one that can mass produce them at a good production yield,” he said. “Taiwanese competitors won’t be able to take Ibiden’s share away by much.” AI semiconductors earn more than 15 per cent of Ibiden’s sales of around 370 billion yen (S$3.2 billion), with that percentage expected to rise further. Nvidia said it’s begun full production of its next-generation Blackwell chips after encountering some initial technical challenges. Over the long term, Nvidia may face growing competition from application-specific chips by Marvell Technology and Broadcom as well as in-house silicon from Alphabet’s Google and Microsoft. In theory, Ibiden should be able to accommodate them all, as AI chip package design and material will likely remain similar to Nvidia’s, according to Kawashima. BLOOMBERGThe Springboks again stood out as South Africa’s top sports team this year, but there was also success for other national sides in the country’s most popular codes. On the rugby field, the Boks continued their momentum from the 2023 Rugby World Cup victory and set out to prove to the few naysayers left that they are undoubtedly the best side in the world. The Boks convincingly won the Rugby Championship with just one loss coming against Argentina, finishing a solid eight points ahead of New Zealand. They also won all three games on their UK tour, beating Scotland, England, and Wales with a combined 106 points scored in that series. Pieter-Steph du Toit became the first South African to be named World Rugby Player of the Year twice and Eben Etzebeth became the most capped Springbok. ALSO READ: Opponents, dates confirmed for Springboks’ home Tests in 2025 Success for Bafana Bafana In football, Bafana Bafana’s year started with a trip to the Africa Cup of Nations finals, where Hugo Broos’ side defied expectations with a brilliant bronze. The highlight of that campaign had to be an incredible 2-0 win in the last 16 over 2022 World Cup semifinalists Morocco. Bafana suffered heartbreak as they were beaten on penalties by Nigeria in the semifinals, but they recovered to beat DR Congo on penalties to claim third place. Buoyed by their AFCON success, Bafana then picked up two momentum-building results in 2026 World Cup qualifying, drawing 1-1 in Nigeria and beating Zimbabwe 3-1 at home. And to finish the year, Broos’ side comfortably qualified for the 2025 Africa Cup of Nations finals in Morocco. Struggling Proteas shine at World Cups Elsewhere, on the cricket pitch, the Proteas men and women did not have the most memorable seasons, but both sides stood up when it counted most. The men’s team won only 21 of their 43 matches across all three formats, while the women’s squad picked up only 12 victories in their 36 games. Both sides reached the T20 World Cup finals, however, with the men ultimately falling to India in the trophy battle in the West Indies and the women slipping against New Zealand in the final in Dubai. The Proteas men also won their last six successive Test matches to qualify for next year’s World Test Championship final. ALSO READ: Proteas hang on for nail-biting win over Pakistan

President Ferdinand ''Bongbong'' Marcos Jr. said Monday that he vetoed more P194 billion worth of line items that are not consistent with his administration's priorities. Aside from that, some special provisions were also subjected to conditional implementation, meaning they would either require the issuance of guidelines and/or impose compliance with pertinent laws, policies, rules, and regulations. Veto is defined as the "power or right vested in one branch of a government to cancel or postpone the decisions, enactments, etc., of another branch, especially the right of a president, governor, or other chief executive to reject bills passed by the legislature." Under the 1987 Constitution, every bill passed by Congress is subject to the President's approval or veto. EXPLAINER: How the President's veto works on the national budget Here is the list of line items that the President had vetoed as he signed the P6.326 trillion budget for fiscal year 2025: According to DPWH Secretary Manny Bonoan, the projects that had been vetoed are actually some of the projects that are not totally supportive of the administration's 8-Point Socioeconomic Agenda. Many of these projects need to be scrutinized and are not yet ready for implementation, Bonoan said. Meanwhile, the following are subject to conditional implementation: National Economic and Development Authority Secretary Arsenio Balisacan said the 2025 General Appropriations Act supports the goals outlined in the Philippine Development Plan 2023-2028, including attaining the medium-term growth targets as approved by the Development Budget Coordination Committee. ''The budget prioritizes strategic investments and social services with substantial allocations to education, health and social welfare programs and infrastructure projects to boost growth and inclusion,'' Balisacan said in a press briefing. ''These investments are crucial for achieving the PDP’s targets related to human capital development and poverty reduction,'' he added. —AOL, GMA Integrated News

Mumbai: Bollywood megastar Shah Rukh Khan, who was last seen in ‘Jawan’, returned to Mumbai from Alibaug along with his family on Sunday. The actor went incognito as he hid his face inside a giant hoodie while holding his pet dog. His wife Gauri Khan and kids were also seen with him at the Gateway Of India. Last month, the superstar celebrated his 59th birthday on November 2. The actor, who entered the film industry after a brief stint in television, capitalised on the opening of India’s economy, and made a seamless shift from grey characters to the king of romance. SRK is inarguably the face of Indian cinema across the world with several honorary doctorate degrees, a Padma Shri, and the French Legion of Honour. Exclusive Shah Rukh Khan with his pet dog clicked at Alibaug jetty as they leave for Mumbai. pic.twitter.com/LUxJ1itNIT The actor single-handedly pulled the Hindi film industry out of the commercial lull induced due to the Covid-19 pandemic. However, the actor’s streak of consecutive success, with ‘Pathaan’ and ‘Jawan’, experienced a bumpy rise with ‘Dunki’. The combo of one of the most successful and influential filmmakers of modern Hindi cinema, and one of the biggest stars in the world, received a more than lukewarm response at the box-office. The film clashed with the Prabhas-starrer ‘Salaar: Part 1 – Ceasefire’ around the same time last year. Both the films eventually suffered because of the clash unlike the recent box-office clash of Ajay Devgn-starrer ‘Singham Again’, and the Kartik Aaryan-starrer ‘Bhool Bhulaiyaa 3’. Meanwhile, SRK and Gauri Khan’s elder son Aryan Khan is making his directorial debut with a streaming series. The series is set against the backdrop of the Hindi film industry. The multi-genre project promises an unabashed take on cinema through the adventures of a charming, ambitious outsider navigating the lanes of B-town. The series blends a high-stakes narrative with self-aware humour. It also features cameos and larger-than-life characters. This upcoming Bollywood series marks the sixth collaboration between Netflix and Red Chillies Entertainment following the hit dark comedy film ‘Darlings’, crime-drama ‘Bhakshak’, the cop-drama film ‘Class of ’83’, the zombie horror series ‘Betaal’, and the spy thriller ‘Bard of Blood’. Produced by Gauri Khan, the series marks Aryan Khan’s debut as a creator and director, and is set to stream on Netflix in 2025.In Gaza's crowded tent camps, women wrestle with a life stripped of privacyJimmy Carter, former US president and Nobel Peace Prize recipient, dead at 100

Lion wakes up Sonakshi Sinha and Zaheer IqbalMUMBAI: Oscar and Grammy-winning music composer A. R. Rahman, who has been appointed the Honorary President of Trinity Laban Conservatoire of Music and Dance, has urged for better investment in talent and building quality infrastructure related to entertainment and art. Rahman’s statement comes in the wake of him being appointed the position at the prestigious institution based in London known for its innovative programs in music, musical theatre, and contemporary dance. The composer will serve in this honorary role for a five-year term, further cementing his influence in the world of performing arts. Rahman reflected on his journey in musical theatre, recalling a significant moment in 2000 when he met music composer Andrew Lloyd Webber. Rahman said, "When I met the king of musical theatre, Andrew Lloyd Webber, he casually asked me, 'Are you going to take the mantle of musical theatre forward?' At the time, I didn't fully grasp what he meant. But as I worked on projects like Bombay Dreams on Broadway and The Lord of the Rings in England and Canada, I began to realize the depth of his vision. It was a serious, visionary thought”. Rahman believes that India has a bright future in the realm of musical theatre, but emphasises the importance of nurturing talent at home. He shared, "If we invest in our talent and build the right infrastructure, we can open up a whole new genre of entertainment in India. But I can't do it alone. I need government support, incentives for performers, musicians, and the infrastructure to support this growth. We are now at a technological crossroads where visuals can be easily generated, but nothing compares to the magic of live performance”. He also spoke about the global success of recent Western tours as a sign of growing demand in the subcontinent. He further mentioned, “Western artists have made billions on recent tours. People want to experience real performances. The honour of being appointed Honorary President of Trinity Laban comes at a perfect time, as it also empowers me to undertake transformational projects in India, particularly through collaborations like the KM Music Conservatory and exciting future initiatives at Trinity Laban”. “The next five years at Trinity Laban could mark a new era of global collaboration in music and dance”, he added.

351 graduates to receive scroll in UTS ninth convocation ceremonyUnlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but $25 to $50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body weight — up to 50 pounds or more in many cases. But roughly 10% to 15% of patients in those trials were “nonresponders” who lost less than 5% of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of patients — as many as 1 in 5 — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results. “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost 7 pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

NEW YORK — A slide for market superstar Nvidia on Dec. 9 knocked Wall Street off its big rally and helped drag U.S. stock indexes down from their records. The S&P 500 fell 0.6 percent Monday, coming off its 57th all-time high of the year so far. The Dow Jones Industrial Average dipped 0.5 percent, and the Nasdaq composite pulled back 0.6 percent from its own record. Nvidia's fall of 2.5 percent was by far the heaviest weight on the S&P 500 after China said it's investigating the company over suspected violations of Chinese anti-monopoly laws. Nvidia has skyrocketed to become one of Wall Street's most valuable companies because its chips are driving much of the world's move into artificial-intelligence technology. That gives its stock's movements more sway on the S&P 500 than nearly every other. Nvidia's drop overshadowed gains in Hong Kong and for Chinese stocks trading in the United States on hopes that China will deliver more stimulus for the world's second-largest economy. Roughly three in seven of the stocks in the S&P 500 rose. The week's highlight for Wall Street will arrive midweek when the latest updates on inflation arrive. NEW YORK — Omnicom is buying Interpublic Group in a stock-for-stock deal that will create an advertising powerhouse with combined annual revenue of almost $26 billion. The New York City agencies have had a hand in iconic marketing campaigns like "Got Milk" for the California Milk Processor Board, "Priceless" for Mastercard, "Because I'm Worth It" for L'Oreal and "Think Different" for Apple. The combined company will be valued at more than $30 billion. It will will keep the Omnicom name and trade under the "OMC" ticker symbol on the New York Stock Exchange. The deal is expected to have annual cost savings of $750 million and is expected to close during the second half of next year. It still needs the approval of Omnicom and Interpublic shareholders. NEW YORK — Activist investor Barington Capital Group is calling on department store retailer Macy's to develop an internal real estate subsidiary, reduce capital expenditures and explore strategic options for its Bloomingdale's and Bluemercury chains among other changes to boost its slumping stock, according to its proposal made public Dec. 9. The presentation came after Barington, which has stakes in such brands as Victoria's Secret, Hanes and Dillard's, has built an undisclosed stake in Macy's. Barington said it has partnered with property owner Thor Equities. They said that Macy's stock is undervalued and that the real estate, including the flagship at Herald Square in Manhattan, is worth between $5 billion and $9 billion. They said Macy's should create a unit to collect market rents from its retail operations and pursue sales and redevelopment opportunities. WASHINGTON — TikTok asked a federal appeals court Dec. 9 to bar the Biden administration from enforcing a law that could lead to a ban on the popular platform until the Supreme Court reviews its challenge to the statute. The legal filing was made after a panel of three judges on the same court sided with the government last week and ruled that the law, which requires China-based TikTok parent ByteDance to divest its stakes in the social media company or face a ban, was constitutional. If the law is not overturned, both TikTok and ByteDance have said the popular app will shut down by Jan. 19. TikTok has more than 170 million American users who would be affected, the companies have said. In a legal filing, attorneys for the two companies wrote that even if a shutdown lasted one month, it would cause TikTok to lose about a third of its daily users in the U.S. "Before that happens, the Supreme Court should have an opportunity, as the only court with appellate jurisdiction over this action, to decide whether to review this exceptionally important case," the filing said. It's not clear if the high court will take up the case. Some legal experts have said the justices are likely to weigh in since the dispute raises novel issues about social media platforms and how far the government could go in protecting national security.Move over, William Nylander. Your little brother has arrived with the Maple Leafs. The Leafs on Friday afternoon announced the signing of forward Alexander Nylander to a one-year contract that carries an average annual value of $775,000 US. Nylander was recalled from the Toronto Marlies, and in a corresponding move, the Leafs placed forward Matthew Knies (upper-body) on injured reserve, retroactive to Nov. 20. In July, the Marlies signed Alex Nylander to a one-year American Hockey League contract. Not long after, he told the ’s Lance Hornby that it would be “a dream come true” to possibly get a chance to play with his older brother (by just under two years) with the Leafs. “I can’t wait for that chance to come,” Alex told Hornby in August. “But I know I have to prove myself first.” A veteran of 121 National Hockey League games with Buffalo, Chicago, Pittsburgh and Columbus — in which he had 25 goals and 24 assists — he did just that with the Marlies. In 14 games, the 26-year-old Nylander scored eight goals and recorded four assists for the Leafs’ farm team. How Nylander lines up at practice on Saturday at the Ford Performance Centre, and then ostensibly used against the Utah Hockey Club on Sunday, remains to be seen. Many in Leafs Nation would love to see him get a shot on a line with his brother, but there’s another rather viable option for coach Craig Berube. In recent games with the Marlies, Nylander was on a line with Fraser Minten and Nikita Grebenkin. The latter two already are with the Leafs, given the club’s long list injuries at forward, and were sharp in the win against Vegas on Wednesday. Either way, the younger Nylander will be eager to make an impact immediately. X: @koshtorontosun

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . MYGN , a leader in genetic testing and precision medicine, announced it will present new data at the 2024 San Antonio Breast Cancer Symposium ® (SABCS), including a spotlight presentation on a breast cancer risk assessment tool that combines a polygenic score for all ancestries. Additional new data will show how Myriad's second-generation tumor-informed molecular residual disease (MRD) assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. "We are very excited to share validation data of our MRD assay. SABCS gives us the opportunity to showcase our clinical expertise in the prevention and treatment of early and advanced breast cancer," said George Daneker, MD, President and Chief Clinical Officer, Oncology, Myriad Genetics. "Myriad is one of the only labs that can offer germline and tumor genomic testing, combined with customizable workflow solutions and point-of-care patient education sessions. Our test results are supported by treatment-focused reporting, concordance checks between germline and tumor genomic results, and a summary sheet designed to help oncologists and breast surgeons interpret actionable insights more effectively." Myriad Genetics Data Presentations Spotlight Presentation: Session 16, PS16-01: Polygenic Risk Date: Thursday, Dec. 12, 2024, 5:30-7:00 pm (CST), Hemisfair Ballroom 3 Presenter: Timothy Simmons, PhD, Biostatistician III, Myriad Genetics The presentation will share longitudinal validation in the UK Biobank of a breast cancer risk assessment tool that combines a polygenic score for all ancestries with traditional risk factors. Rapid-Fire Presentation: RF1-06 Date: Wednesday, Dec. 11, 2024, 12:00-12:50 pm (CST), Hall 1 Presenter: Katie Johansen Taber, PhD, Vice President, Clinical Product Research & Partnerships, Myriad Genetics Dr. Johansen Taber will share data detailing the association of polygenic-based breast cancer risk prediction with patient management. Poster Presentation: P2-04-23 Date: Wednesday, Dec. 11, 2024, 5:30-7:00 pm (CST), Halls 2-3 Presenter: Ashley Acevedo, PhD, Staff Computational Scientist, Myriad Genetics This poster shares the analytical validation of a high-definition tumor-informed Molecular Residual Disease (MRD) assay to demonstrate robust detection at low-tumor fractions, which are common in breast cancer. Poster Presentation: P3-02-10 Date: Thursday, Dec. 12, 2024, 12:30-2:00 pm (CST), Halls 2-3 Presenter: Holly Pederson, MD, Cleveland Clinic Dr. Pederson will share her evaluation of a polygenic risk score as a predictor of breast cancer, triple-negative breast cancer, and early-onset disease in Hispanic women. In addition to data presentations, Myriad will welcome attendees to its booth (#1327) during exhibition hours. Among the Myriad products highlighted in the company's SABCS exhibit are: MyRisk ® Hereditary Cancer Test evaluates 48 genes to help healthcare providers identify their patients' risk of developing 11 different types of hereditary cancer. MyRisk's clear, actionable results are the foundation for personalized care plans to help patients make confident, informed decisions about medical management. MyRisk with RiskScore ® provides unaffected patients with a comprehensive, personalized assessment of the five-year risk and remaining lifetime risk of developing breast cancer. Precise Tumor ® Molecular Profile Test is a pan-cancer solid tumor comprehensive genomic profiling test that helps clinicians with straightforward interpretations, prioritization of therapies, and the next steps specific to each patient's genomic result. MyChoice ® CDx is one of the most comprehensive homologous recombination deficiency (HRD) tests available, enabling physicians to identify patients with tumors that have lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. The MyChoice test comprises tumor sequencing of the BRCA1 and BRCA2 genes and a composite of three proprietary technologies (loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions). EndoPredict ® Breast Cancer Prognostic Test is for patients with ER+ , HER2- , node negative or node positive breast cancer. The test provides three individualized results used to help determine the most appropriate breast cancer treatment. About Myriad Genetics Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com . Safe Harbor Statement This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including that the company will present new data at SABCS and that the company's new data that will be shared at SABCS will show how the company's second-generation tumor-informed MRD assay demonstrated high sensitivity, specificity and measurement accuracy, which, together, will facilitate improved resolution in residual-disease detection and extend lead times in recurrence detection. These "forward-looking statements" are management's expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company's filings with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K filed on February 28, 2024, as well as any updates to those risk factors filed from time to time in the company's Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. Investor Contact Matt Scalo (801) 584-3532 IR@myriad.com Media Contact Glenn Farrell (385) 318-3718 PR@myriad.com © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Church to lead key aspects of celebration